Mr Will Sarakbi

Professional statement

Mr Will Sarakbi is a highly respected consultant oncoplastic breast surgeon. He specialises in both aesthetic and cancer breast surgery. He has over 10 years of experience in the field of aesthetic breast surgery and has performed over 1,000 breast augmentations and 600 breast reductions. His private practice is based at Shirley Oaks Hospital and the prestigious Cadogan clinic in Chelsea.

Mr Sarakbi qualified from St George’s, The University of London in 2001. After completing his basic surgical training in the South East of England, he spent some time in full-time research focusing on breast cancer biology and examining the role of molecular markers, such STS and OATP as prognostic indicators in breast cancer. He was awarded a masters degree in surgery from the University of London shortly after completing this research.

Impressively, Mr Sarakbi's research work has generated over 22 papers in peer-reviewed journals to date, and he has presented his findings in national and international conferences in the UK, Europe, and the USA. Mr Sarakbi continued his higher surgical training in the London Deanery, spending almost two years at Guys and St Thomas’ Hospital. He was elected to the post of president of the National Breast Trainees Association (The Mammary Fold) in 2010, and subsequently to the post of president of the Surgical Oncology Trainees Association (SOTA) two years later.

Mr Sarakbi was notably selected for the prestigious national Aesthetic and Reconstructive Fellowship, which provided him with world-class training in both cosmetic and reconstructive breast surgery. He also spent time training in France at the Leon-Bérard Centre in Lyon, working with internationally renowned reconstructive surgeons, where he mastered advanced techniques in breast reconstruction and cosmetic breast surgery, including lipomodelling (fat transfer).

He mainly specialises in breast enlargement, breast implant replacement, breast lift, breast reconstruction, breast reduction, and nipple reduction. Mr Sarakbi is a present member of the Intensity-Modulated Partial Organ Radiotherapy Trial (IMPORT) trial management group, one of the largest currently running radiotherapy trials in the UK funded by Cancer Research UK, investigating new techniques of delivering radiotherapy in breast cancer.